The role of small molecules in musculoskeletal regeneration

Regenerative Medicine

Volumn 7, Issue 4, 2012, Pages 535-549

  Lo, Kevin W H ^a,b   Ashe, Keshia M ^a,c   Kan, Ho Man ^a   Laurencin, Cato T ^a,c  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

bone regeneration; growth factor; orthopedic; osteogenesis; small molecule; tissue engineering

Indexed keywords

AGENTS AFFECTING METABOLISM; BERBERINE; BONE MORPHOGENETIC PROTEIN; CERIVASTATIN; FLUINDOSTATIN; GENISTIN; ICARIIN; MEVINOLIN; OIC A006; OLANZAPINE; OSTHOLE; PHENAMIL; PROSTAGLANDIN DERIVATIVE; PSORALEN; PUERARIN; PURMORPHAMINE; RAPAMYCIN; RESVERATROL; SIMVASTATIN; TACROLIMUS; TAK 778; UNCLASSIFIED DRUG; WAY 316606;

ANGIOGENESIS; BONE DEFECT; BONE DEVELOPMENT; BONE MINERALIZATION; BONE REGENERATION; CELL DIFFERENTIATION; CELL FUNCTION; DRUG MECHANISM; HUMAN; IMMUNOGENICITY; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN STABILITY; REGENERATIVE MEDICINE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; MUSCULOSKELETAL SYSTEM; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOCLASTS; OSTEOGENESIS; REGENERATION; SMALL MOLECULE LIBRARIES;

EID: 84864264096     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.12.33     Document Type: Review

References (188)

1. Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone. Biology and clinical applications. J. Bone Joint Surg. Am. 84-A(6), 1032-1044 (2002).
2. Wang EA, Rosen V, D'Alessandro JS et al. Recombinant human bone morphogenetic protein induces bone formation. Proc. Natl Acad. Sci. USA 87(6), 2220-2224 (1990).
3. Urist MR. Bone: Formation by autoinduction. Science 150(698), 893-899 (1965).
4. White AP, Vaccaro AR, Hall JA, Whang PG, Friel BC, McKee MD. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int. Orthop. 31(6), 735-741 (2007). (Pubitemid 350160312)
5. McKay WF, Peckham SM, Badura JM. A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft). Int. Orthop. 31(6), 729-734 (2007). (Pubitemid 350160311)
6. Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: The road from laboratory to clinic, part II (BMP delivery). J. Tissue Eng. Regen. Med. 2(2-3), 81-96 (2008).
7. Rubin MR, Bilezikian JP. The anabolic effects of parathyroid hormone therapy. Clin. Geriatr. Med. 19(2), 415-432 (2003). (Pubitemid 36514527)
8. Deal C, Gideon J. Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosis. Cleve. Clin. J. Med. 70(7), 585-586, 589-590, 592-594 passim (2003).
9. Holick MF. PTH (1-34): A novel anabolic drug for the treatment of osteoporosis. South. Med. J. 98(11), 1114-1117 (2005). (Pubitemid 41780351)
10. Garrett IR. Anabolic agents and the bone morphogenetic protein pathway. Curr. Top. Dev. Biol. 78, 127-171 (2007).
11. Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: The road from the laboratory to the clinic, part I (basic concepts). J. Tissue Eng. Regen. Med. 2(1), 1-13 (2008).
12. Dingermann T. Recombinant therapeutic proteins: Production platforms and challenges. Biotechnol. J. 3(1), 90-97 (2008). (Pubitemid 351200935)
13. Ratelade J, Miot MC, Johnson E, Betton JM, Mazodier P, Benaroudj N. Production of recombinant proteins in the lon-deficient BL21(DE3) strain of Escherichia coli in the absence of the DnaK chaperone. Appl. Environ. Microbiol. 75(11), 3803-3807 (2009).
14. Schein CH. Production of soluble recombinant proteins in bacteria. Biotechnology 7, 1141-1149 (1989). (Pubitemid 19262571)
15. Egusa H, Saeki M, Doi M et al. A small-molecule approach to bone regenerative medicine in dentistry. J. Oral Biosci. 52(2), 107-118 (2010).
16. Walker DH, Wright NM. Bone morphogenetic proteins and spinal fusion. Neurosurg. Focus 13(6), e3 (2002).
17. Hanley DA, Watson PH, Hodsman AB, Dempster DW. Pharmacological mechanisms of therapeutics: Parathyroid hormone. Prin. Bone Biol. 2, 1661-1695 (2008).
18. Hwang CJ, Vaccaro AR, Lawrence JP et al. Immunogenicity of bone morphogenetic proteins. J. Neurosurg. Spine 10(5), 443-451 (2009).
19. Gong Z, Zhou S, Cao J, Gu X. Effects of recombinant human basic fibroblast growth factor on cell proliferation during mandibular fracture healing in rabbits. Chin. J. Traumatol. 4(2), 110-112 (2001).
20. Hollinger JO, Hart CE, Hirsch SN, Lynch S, Friedlaender GE. Recombinant human platelet-derived growth factor: Biology and clinical applications. J. Bone Joint Surg. Am. 90(Suppl. 1), 48-54 (2008). (Pubitemid 351329121)
21. Devescovi V, Leonardi E, Ciapetti G, Cenni E. Growth factors in bone repair. Chir. Organi Mov. 92(3), 161-168 (2008).
22. Ripamonti U, Ferretti C, Teare J, Blann L. Transforming growth factor-beta isoforms and the induction of bone formation: Implications for reconstructive craniofacial surgery. J. Craniofac. Surg. 20(5), 1544-1555 (2009).
23. Lo KW-H, Kan HM, Ashe KM, Laurencin CT. The small molecule PKA-selective cyclic AMP analogue as an inducer of osteoblast-like cells differentiation and mineralization. J. Tissue Eng. Regen. Med. 6, 40-48 (2012).
24. Lo KW, Ulery BD, Deng M, Ashe KM, Laurencin CT. Current patents on osteoinductive molecules for bone tissue engineering. Recent Patents Biomed. Eng. 4(3), 153-167 (2012).
25. Lo KW-H, Ulery BD, Ashe KM, Laurencin CT. Studies of bone morphogenetic protein based surgical repair. Adv. Drug Deliv. Rev. doi:10.1016/j.addr.03.014 (2012) (Epub ahead of print).
26. Blaich G, Janssen B, Roth G, Salfeld J. Overview: Differentiating issues in the development of macromolecules compared with small molecules. In: HANDBOOK of Pharmaceutical Biotechnology. John Wiley & Sons Inc., NJ, USA, 89-123 (2006).
27. van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res. 17(10), 1159-1167 (2000).
28. Fu K, Klibanov AM, Langer R. Protein stability in controlled-release systems. Nat. Biotechnol. 18(1), 24-25 (2000). (Pubitemid 30041164)
29. Wieghaus KA, Capitosti SM, Anderson CR et al. Small molecule inducers of angiogenesis for tissue engineering. Tissue Eng. 12(7), 1903-1913 (2006). (Pubitemid 44162849)
30. Pyeritz RE. A small molecule for a large disease. N. Engl. J. Med. 358(26), 2829-2831 (2008).
31. Le GT, Abbenante G. Inhibitors of TACE and caspase-1 as anti-inflammatory drugs. Curr. Med. Chem. 12(25), 2963-2977 (2005).
32. Carroll SF. Discovery and Nonclinical Development. Springer, NY, USA, 84-106 (2007).
33. Lo KWH, Ashe KM, Kan HM, Lee DA, Laurencin CT. Activation of cyclic AMP/ protein kinase A signaling pathway enhances osteoblast cell adhesion on biomaterials for regenerative engineering. J. Orthop. Res. 29(4), 602-608 (2011).
34. Siddappa R, Doorn J, Liu J et al. Timing, rather than the concentration of cyclic AMP, correlates to osteogenic differentiation of human mesenchymal stem cells. J. Tissue Eng. Regen. Med. 4(5), 356-365 (2010).
35. Kinto N, Iwamoto M, Enomoto-Iwamoto M et al. Fibroblasts expressing sonic hedgehog induce osteoblast differentiation and ectopic bone formation. FEBS Lett. 404(2-3), 319-323 (1997). (Pubitemid 27113476)
36. Nakamura T, Aikawa T, Iwamoto-Enomoto M et al. Induction of osteogenic differentiation by hedgehog proteins. Biochem. Biophys. Res. Commun. 237(2), 465-469 (1997). (Pubitemid 27406054)
37. Zwijsen A, Verschueren K, Huylebroeck D. New intracellular components of bone morphogenetic protein/Smad signaling cascades. FEBS Lett. 546(1), 133-139 (2003). (Pubitemid 36782294)
38. Hu Y, Chan E, Wang SX, Li B. Activation of p38 mitogen-activated protein kinase is required for osteoblast differentiation. Endocrinology 144(5), 2068-2074 (2003). (Pubitemid 36543347)
39. Lin FH, Chang JB, Brigman BE. Role of mitogen-activated protein kinase in osteoblast differentiation. J. Orthop. Res. 29(2), 204-210 (2011).
40. Gaur T, Lengner CJ, Hovhannisyan H et al. Canonical Wnt signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J. Biol. Chem. 280(39), 33132-33140 (2005). (Pubitemid 41397109)
41. Liu G, Vijayakumar S, Grumolato L et al. Canonical Wnts function as potent regulators of osteogenesis by human mesenchymal stem cells. J. Cell. Biol. 185(1), 67-75 (2009).
42. Friedenstein AY. Induction of bone tissue by transitional epithelium. Clin. Orthop. Relat. Res. 59, 21-37 (1968).
43. Wilson-Hench J. Osteoinduction. In: PROGRESS in Biomedical Engineering: DEFINITIONS in Biomaterials. Williams D (Ed.). Elsevier, The Netherlands, 29 (1987).
44. Barradas AM, Yuan H, van Blitterswijk CA, Habibovic P. Osteoinductive biomaterials: Current knowledge of properties, experimental models and biological mechanisms. Eur. Cell. Mater. 21, 407-429; discussion 429 (2011).
45. Bentz H, Nathan RM, Rosen DM et al. Purification and characterization of a unique osteoinductive factor from bovine bone. J. Biol. Chem. 264, 20805-20810 (1989). (Pubitemid 20009282)
46. Yoshida K, Bessho K, Fujimura K et al. Osteoinduction capability of recombinant human bone morphogenetic protein-2 in intramuscular and subcutaneous sites: An experimental study. J. Craniomaxillofac. Surg. 26(2), 112-115 (1998). (Pubitemid 28254720)
47. Habibovic P, Sees TM, van den Doel MA, van Blitterswijk CA, de Groot K. Osteoinduction by biomaterials - physicochemical and structural influences. J. Biomed. Mater. Res. A 77(4), 747-762 (2006). (Pubitemid 47233556)
48. Houshmand B, Hassanizade R, Eslami B et al. Simuvastatin and lovastatin induce ectopic bone formation in rat subcutaneous tissue. J. Periodontol. Implant Dent. 2(1), 12-16 (2011).
49. Mundy G, Garrett R, Harris S et al. Stimulation of bone formation in vitro and in rodents by statins. Science 286(5446), 1946-1949 (1999). (Pubitemid 129515901)
50. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem. Biophys. Res. Commun. 271(3), 688-692 (2000). (Pubitemid 30444689)
51. Gutierrez G, Garrett IR, Rossini G. Dermal application of lovastatin to rats causes greater increases in bone formation and plasma concentrations that when administered by oral gavage. J. Bone Miner. Res. 15, S427 (2000).
52. Whang K, Zhao M, Qiao M et al. Administration of lovastatin locally in low doses in a novel delivery system induces prolonged bone formation. J. Bone Miner. Res. 15, S225 (2000).
53. Maeda T, Matsunuma A, Kawane T, Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem. Biophys. Res. Commun. 280(3), 874-877 (2001). (Pubitemid 32924513)
54. Garrett IR, Gutierrez G, Mundy GR. Statins and bone formation. Curr. Pharm. Des. 7(8), 715-736 (2001). (Pubitemid 32427770)
55. Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler. Thromb. Vasc. Biol. 21(10), 1636-1641 (2001). (Pubitemid 34215584)
56. Edwards CJ, Spector TD. Statins as modulators of bone formation. Arthritis Res. 4(3), 151-153 (2002). (Pubitemid 34460752)
57. Chen PY, Sun JS, Tsuang YH, Chen MH, Weng PW, Lin FH. Simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway. Nutr. Res. 30(3), 191-199 (2010).
58. Eichler K, Puhan MA, Bachmann LM. The role of statins in primary prevention of cardiovascular disease. Arch. Intern. Med. 167(10), 1100; author reply 1100-1101 (2007).
59. Cushenberry L, Debittner MR. Potential use of HMG-CoA reductase inhibitors for osteoporosis. Ann. Pharmacother. 36, 671-678 (2002). (Pubitemid 34270285)
60. Ohba S, Nakajima K, Komiyama Y et al. A novel osteogenic helioxanthin-derivative acts in a BMP-dependent manner. Biochem. Biophys. Res. Commun. 357(4), 854-860 (2007). (Pubitemid 46693650)
61. Yoshikawa T, Nakajima H, Yamada E et al. In vivo osteogeneic capability of cultured allogeneic bone in porous hydroxvapatite: Immunosuppressive and osteogeneic potential of FK506 in vivo. J. Bone Miner. Res. 15, 1147-1157 (2000). (Pubitemid 30350078)
62. Voggenreiter G, Assenmacher S, Kreuzfelder E et al. Immunosuppression with FK506 increases bone induction in demineralized isogeneic and xenogeneic bone matrix in the rat. J. Bone Miner. Res. 15(9), 1825-1834 (2000). (Pubitemid 30666236)
63. Tang L, Ebara S, Kawasaki S, Wakabayashi S, Nikaido T, Takaoka K. FK506 enhanced osteoblastic differentiation in mesenchymal cells. Cell Biol. Int. 26(1), 75-84 (2002). (Pubitemid 34174409)
64. Kugimiya F, Yano F, Ohba S et al. Mechanism of osteogenic induction by FK506 via BMP/ Smad pathways. Biochem. Biophys. Res. Commun. 338(2), 872-879 (2005). (Pubitemid 41597724)
65. Yoshikawa T, Nakajima H, Uemura T et al. In vitro bone formation induced by immunosuppressive agent tacrolimus hydrate (FK506). Tissue Eng. 11(3-4), 609-617 (2005). (Pubitemid 40632575)
66. Zhao J, Ohba S, Shinkai M, Chung UI, Nagamune T. Icariin induces osteogenic differentiation in vitro in a BMP-and Runx2-dependent manner. Biochem. Biophys. Res. Commun. 369(2), 444-448 (2008).
67. Zhao J, Ohba S, Komiyama Y, Shinkai M, Chung UI, Nagamune T. Icariin: A potential osteoinductive compound for bone tissue engineering. Tissue Eng. Part A 16(1), 233-243 (2010).
68. Wei H, Zili L, Yuanlu C et al. Effect of icariin on bone formation during distraction osteogenesis in the rabbit mandible. Int. J. Oral Maxillofac. Surg. 40(4), 413-418 (2011).
69. Ogawa T, Tokuda M, Tomizawa K et al. Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast like osteosarcoma (ROS 17/2.8) cells. Biochem. Biophys. Res. Commun. 249, 226-230 (1998). (Pubitemid 28418724)
70. Lee KW, Yook JY, Son MY et al. Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway. Stem Cells Dev. 19(4), 557-568 (2010).
71. Park KW, Waki H, Kim WK. The small molecule phenamil induces osteoblast differentiation and mineralization. Mol. Cell Biol. 29(14), 3905-3914 (2009).
72. Nakajima K, Komiyama Y, Hojo H et al. Enhancement of bone formation ex vivo and in vivo by a helioxanthin-derivative. Biochem. Biophys. Res. Commun. 395(4), 502-508 (2010).
73. Sawada S, Suzuki G, Kawase Y, Takaku F. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J. Immunol. 139(6), 1797-1803 (1987). (Pubitemid 17141605)
74. Thomson AW. FK-506 - how much potential? Immunol. Today 10(1), 6-9 (1989).
75. Chang JY, Sehgal SN, Bansbach CC. FK506 and rapamycin: Novel pharmacological probes of the immune response. Trends Pharmacol. Sci. 12(6), 218-223 (1991).
76. Kotobuki N, Katsube Y, Katou Y, Tadokoro M, Hirose M, Ohgushi H. In vivo survival and osteogenic differentiation of allogeneic rat bone marrow mesenchymal stem cells (MSCs). Cell Transplant. 17(6), 705-712 (2008).
77. Lim DJ, Park BK, Jang WG et al. Regulation of bone formation using rapamycin-induced BMP2 expression system: Influence of implanted cell number Mol. Cell. Toxicol. 6(2), 187-194 (2010).
78. Chan MC, Nguyen PH, Davis BN et al. A novel regulatory mechanism of the bone morphogenetic protein (BMP) signaling pathway involving the carboxyl-terminal tail domain of BMP type II receptor. Mol. Cell Biol. 27(16), 5776-5789 (2007). (Pubitemid 47257833)
79. Poppe H, Rybalkin SD, Rehmann H et al. Cyclic nucleotide analogs as probes of signaling pathways. Nat. Methods 5(4), 277-278 (2008). (Pubitemid 351455143)
80. Miyamoto K, Suzuki H, Yamamoto S et al. Prostaglandin E2-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4, XT-611, in the in vitro bone marrow culture. J. Bone Miner. Res. 18(8), 1471-1477 (2003). (Pubitemid 41070801)
81. Han CY, Wang Y, Yu L et al. Small molecules with potent osteogenic-inducing activity in osteoblast cells. Bioorg. Med. Chem. Lett. 19(5), 1442-1445 (2009).
82. Wu X, Ding S, Ding Q, Gray NS, Schultz PG. A small molecule with osteogenesis-inducing activity in multipotent mesenchymal progenitor cells. J. Am. Chem. Soc. 124(49), 14520-14521 (2002). (Pubitemid 35425009)
83. Beloti MM, Bellesini LS, Rosa AL. Purmorphamine enhances osteogenic activity of human osteoblasts derived from bone marrow mesenchymal cells. Cell Biol. Int. 29(7), 537-541 (2005). (Pubitemid 41138216)
84. Wu X, Walker J, Zhang J, Ding S, Schultz PG. Purmorphamine induces osteogenesis by activation of the hedgehog signaling pathway. Chem. Biol. 11(9), 1229-1238 (2004). (Pubitemid 39282798)
85. Sinha S, Chen JK. Purmorphamine activates the Hedgehog pathway by targeting Smoothened. Nat. Chem. Biol. 2(1), 29-30 (2006).
86. Oda T, Notoya K, Gotoh M et al. Synthesis of novel 2-benzothiopyran and 3-benzothiepin derivatives and their stimulatory effect on bone formation. J. Med. Chem. 42, 751-760 (1999). (Pubitemid 29110790)
87. Hoshino T, Muranishi H, Saito K et al. Enhancement of fracture repair in rats with streptozotocin-induced diabetes by a single injection of biodegradable microcapsules containing a bone formation stimulant, TAK-778. J. Biomed. Mater. Res. 51(3), 299-306 (2000). (Pubitemid 30452131)
88. Rosa AL, Beloti MM. TAK-778 enhances osteoblast differentiation of human bone marrow cells. J. Cell. Biochem. 89(6), 1148-1153 (2003). (Pubitemid 36959382)
89. Rosa AL, Beloti MM. TAK-778 enhances osteoblast differentiation of human bone marrow cells via an estrogen-receptor-dependent pathway. J. Cell. Biochem. 91(4), 749-755 (2004).
90. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation. Cell 89(5), 747-754 (1997). (Pubitemid 27516177)
91. Schroeder TM, Jensen ED, Westendorf JJ. Runx2: A master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res. C Embryo Today 75(3), 213-225 (2005). (Pubitemid 41456323)
92. Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. Expert Opin. Ther. Targets 13(4), 485-496 (2009).
93. Milat F, Ng KW. Is Wnt signalling the final common pathway leading to bone formation? Mol. Cell. Endocrinol. 310(1-2), 52-62 (2009).
94. Agholme F, Aspenberg P. Wnt signaling and orthopedics, an overview. Acta Orthop. 82(2), 125-130 (2011).
95. Bodine PV, Stauffer B, Ponce-de-Leon H et al. A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation. Bone 44(6), 1063-1068 (2009).
96. Moore WJ, Kern JC, Bhat R et al. Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides. J. Med. Chem. 52(1), 105-116 (2009).
97. Moore WJ, Kern JC, Bhat R et al. Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides: Part II. Bioorg. Med. Chem. 18(1), 190-201 (2010).
98. Baksh D, Boland GM, Tuan RS. Cross-talk between Wnt signaling pathways in human mesenchymal stem cells leads to functional antagonism during osteogenic differentiation. J. Cell. Biochem. 101(5), 1109-1124 (2007). (Pubitemid 47253714)
99. Lin GL, Hankenson KD. Integration of BMP, Wnt, and Notch signaling pathways in osteoblast differentiation. J. Cell. Biochem. 112(12), 3491-3501 (2011).
100. Amantea CM, Kim WK, Meliton V, Tetradis S, Parhami F. Oxysterol-induced osteogenic differentiation of marrow stromal cells is regulated by Dkk-1 inhibitable and PI3-kinase mediated signaling. J. Cell. Biochem. 105(2), 424-436 (2008).
101. Brey DM, Motlekar NA, Diamond SL, Mauck RL, Garino JP, Burdick JA. High-throughput screening of a small molecule library for promoters and inhibitors of mesenchymal stem cell osteogenic differentiation. Biotechnol. Bioeng. 108(1), 163-174 (2011).
102. Hojo H, Igawa K, Ohba S et al. Development of high-throughput screening system for osteogenic drugs using a cell-based sensor. Biochem. Biophys. Res. Commun. 376(2), 375-379 (2008).
103. Cai M, Liu X, Shao J et al. OIC-A006 promotes osteogenesis in vitro and in vivo. Pharmazie 63(10), 751-756 (2008).
104. Jabbarzadeh E, Starnes T, Khan YM et al. Induction of angiogenesis in tissue-engineered scaffolds designed for bone repair: A combined gene therapy-cell transplantation approach. Proc. Natl Acad. Sci. USA 105(32), 11099-11104 (2008).
105. Keramaris NC, Calori GM, Nikolaou VS, Schemitsch EH, Giannoudis PV. Fracture vascularity and bone healing: A systematic review of the role of VEGF. Injury 39(Suppl. 2), S45-S57 (2008).
106. Sefcik LS, Petrie Aronin CE, Botchwey EA. Engineering vascularized tissues using natural and synthetic small molecules. Organogenesis 4(4), 215-227 (2008).
107. Sefcik LS, Petrie Aronin CE, Wieghaus KA, Botchwey EA. Sustained release of sphingosine 1-phosphate for therapeutic arteriogenesis and bone tissue engineering. Biomaterials 29(19), 2869-2877 (2008).
108. Papapoulos SE, Landman JO, Bijvoet OL et al. The use of bisphosphonates in the treatment of osteoporosis. Bone 13(Suppl. 1), S41-S49 (1992).
109. Tayalia P, Mooney DJ. Controlled growth factor delivery for tissue engineering. Adv. Mater. 21, 3269-3285 (2009).
110. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting Curr. Opin. Solid State Mater. Sci. 6(4), 319-327 (2002). (Pubitemid 36238389)
111. Pridgen EM, Langer R, Farokhzad OC. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine (Lond.) 2(5), 669-680 (2007). (Pubitemid 350268246)
112. Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int. J. Pharm. 364(2), 298-327 (2008).
113. Oredein-McCoy O, Krogman NR, Weikel AL, Hindenlang MD, Allcock HR, Laurencin CT. Novel factor-loaded polyphosphazene matrices: Potential for driving angiogenesis. J. Microencapsul. 26(6), 544-555 (2009).
114. Peach MS, Kumbar SG, Brown JL, Laurencin CT. Recent developments in nanoparticle based targeted delivery of chemotherapeutics. Curr. Bioactive Compunds 5, 170-184 (2009).
115. Cushnie EK, Khan YM, Laurencin CT. Tissue-engineered matrices as functional delivery systems: Adsorption and release of bioactive proteins from degradable composite scaffolds. J. Biomed. Mater. Res. A 94(2), 568-575 (2011).
116. Siddappa R, Martens A, Doorn J et al. cAMP/PKA pathway activation in human mesenchymal stem cells in vitro results in robust bone formation in vivo. Proc. Natl Acad. Sci. USA 105(20), 7281-7286 (2008). (Pubitemid 351754469)
117. Morozowich NL, Weikel AL, Nichol JL et al. Polyphosphazene containing vitamin substituents: Synthesis, characterization and hydrolytic sensitivity. Macromolecules 44, 1355-1365 (2011).
118. Laurencin CT. Musculoskeletal regenerative engineering: Taking on the grand challenges. Rejuvenation Res. 10, 37S (2008).
119. Benoit DS, Nuttelman CR, Collins SD, Anseth KS. Synthesis and characterization of a fluvastatin-releasing hydrogel delivery system to modulate hMSC differentiation and function for bone regeneration. Biomaterials 27(36), 6102-6110 (2006). (Pubitemid 44414974)
120. Leach JK, Mooney DJ. Bone engineering by controlled delivery of osteoinductive molecules and cells. Expert Opin. Biol. Ther. 4(7), 1015-1027 (2004). (Pubitemid 38937545)
121. Hamidi M, Azadi A, Rafiei P. Hydrogel nanoparticles in drug delivery. Adv. Drug Deliv. Rev. 60(15), 1638-1649 (2008).
122. Haller MF, Saltzman WM. Nerve growth factor delivery systems. J. Control Release 53(1-3), 1-6 (1998). (Pubitemid 28218684)
123. Ladewig K. Drug delivery in soft tissue engineering. Expert Opin. Drug Deliv. 8(9), 1175-1188 (2011).
124. Saltzman WM, Olbricht WL. Building drug delivery into tissue engineering. Nat. Rev. Drug Discov. 1(3), 177-186 (2002). (Pubitemid 37361421)
125. Tsang VL, Bhatia SN. Three-dimensional tissue fabrication. Adv. Drug Deliv. Rev. 56(11), 1635-1647 (2004). (Pubitemid 39177693)
126. Gkioni K, Leeuwenburgh SC, Douglas TE, Mikos AG, Jansen JA. Mineralization of hydrogels for bone regeneration. Tissue Eng. Part B Rev. 16(6), 577-585 (2010).
127. Cheng F, Choy YB, Choi H, Kim KK. Modeling of small-molecule release from crosslinked hydrogel microspheres: Effect of crosslinking and enzymatic degradation of hydrogel matrix. Int. J. Pharm. 403(1-2), 90-95 (2011).
128. Zhu J, Marchant RE. Design properties of hydrogel tissue-engineering scaffolds. Expert Rev. Med. Devices 8(5), 607-626 (2011).
129. Van Tomme SR, Storm G, Hennink WE. In situ gelling hydrogels for pharmaceutical and biomedical applications. Int. J. Pharm. 355(1-2), 1-18 (2008).
130. Su K, Shi X, Varshney RR, Wang DA. Transplantable delivery systems for in situ controlled release of bisphosphonate in orthopedic therapy. Expert Opin. Drug Deliv. 8(1), 113-126 (2011).
131. Verron E, Gauthier O, Janvier P et al. In vivo bone augmentation in an osteoporotic environment using bisphosphonate-loaded calcium deficient apatite. Biomaterials 31(30), 7776-7784 (2010).
132. Lalatonne Y, Monteil M, Jouni H et al. Superparamagnetic bifunctional bisphosphonates nanoparticles: A potential MRI contrast agent for osteoporosis therapy and diagnostic. J. Osteoporos. 2010, 747852 (2010).
133. Seshima H, Yoshinari M, Takemoto S et al. Control of bisphosphonate release using hydroxyapatite granules. J. Biomed. Mater. Res. B Appl. Biomater. 78(2), 215-221 (2006). (Pubitemid 44167721)
134. Panzavolta S, Torricelli P, Bracci B, Fini M, Bigi A. Alendronate and pamidronate calcium phosphate bone cements: Setting properties and in vitro response of osteoblast and osteoclast cells. J. Inorg. Biochem. 103(1), 101-106 (2009).
135. Nair SL, Laurencin CT. Polymers as biomaterials for tissue engineering and controlled drug delivery. Adv. Biochem. Eng. Biotechnol. 102, 47-90 (2006). (Pubitemid 44608153)
136. Weiss WA, Taylor SS, Shokat KM. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat. Chem. Biol. 3(12), 739-744 (2007). (Pubitemid 350126879)
137. Friedman MS, Long MW, Hankenson KD. Osteogenic differentiation of human mesenchymal stem cells is regulated by bone morphogenetic protein-6. J. Cell. Biochem. 98(3), 538-554 (2006). (Pubitemid 43727174)
138. Sumanasinghe RD, Bernacki SH, Loboa EG. Osteogenic differentiation of human mesenchymal stem cells in collagen matrices: Effect of uniaxial cyclic tensile strain on bone morphogenetic protein (BMP-2) mRNA expression. Tissue Eng. 12(12), 3459-3465 (2006). (Pubitemid 46037169)
139. Marie PJ, Fromigue O. Osteogenic differentiation of human marrow-derived mesenchymal stem cells. Regen. Med. 1(4), 539-548 (2006).
140. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 284(5411), 143-147 (1999). (Pubitemid 29282067)
141. Wu W, Ye Z, Zhou Y, Tan WS. AICAR, a small chemical molecule, primes osteogenic differentiation of adult mesenchymal stem cells. Int. J. Artif. Organs 34(12), 1128-1136 (2012).
142. Baek KH, Lee WY, Oh KW et al. The effect of simvastatin on the proliferation and differentiation of human bone marrow stromal cells. J. Korean Med. Sci. 20(3), 438-444 (2005).
143. Ruiz-Gaspa S, Nogues X, Enjuanes A et al. Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J. Cell. Biochem. 101(6), 1430-1438 (2007). (Pubitemid 47242774)
144. Pagkalos J, Cha JM, Kang Y, Heliotis M, Tsiridis E, Mantalaris A. Simvastatin induces osteogenic differentiation of murine embryonic stem cells. J. Bone Miner. Res. 25(11), 2470-2478 (2010).
145. Dai W, Dong J, Fang T, Uemura T. Stimulation of osteogenic activity in mesenchymal stem cells by FK506. J. Biomed. Mater. Res. A 86(1), 235-243 (2008). (Pubitemid 351799504)
146. Koh JT, Ge C, Zhao M et al. Use of a stringent dimerizer-regulated gene expression system for controlled BMP2 delivery. Mol. Ther. 14, 684-691 (2006). (Pubitemid 44507713)
147. Mok SK, Chen WF, Lai WP et al. Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells. Br. J. Pharmacol. 159(4), 939-949 (2010).
148. Aghaloo TL, Amantea CM, Cowan CM et al. Oxysterols enhance osteoblast differentiation in vitro and bone healing in vivo. J. Orthop. Res. 25(11), 1488-1497 (2007). (Pubitemid 350205597)
149. Zhang Y, Zeng X, Zhang L, Zheng X. Stimulatory effect of puerarin on bone formation through activation of PI3K/Akt pathway in rat calvaria osteoblasts. Planta Med. 73(4), 341-347 (2007). (Pubitemid 46910416)
150. Wong R, Rabie B. Effect of puerarin on bone formation. Osteoarthritis Cartilage 15(8), 894-899 (2007). (Pubitemid 47209258)
151. Heim M, Frank O, Kampmann G et al. The phytoestrogen genistein enhances osteogenesis and represses adipogenic differentiation of human primary bone marrow stromal cells. Endocrinology 145(2), 848-859 (2004). (Pubitemid 38183829)
152. Wong RW, Rabie AB. Effect of genistin on bone formation. Front. Biosci. (Elite Ed.) 2, 764-770 (2010).
153. Tang DZ, Yang F, Yang Z. Psoralen stimulates osteoblast differentiation through activation of BMP signaling. Biochem. Biophys. Res. Commun. 405(2), 256-261 (2011).
154. Wong RW, Rabie AB. Effect of psoralen on bone formation. J. Orthop. Res. 29(2), 158-164 (2011).
155. Tang DZ, Hou W, Zhou Q et al. Osthole stimulates osteoblast differentiation and bone formation by activation of beta-catenin-BMP signaling. J. Bone Miner. Res. 25(6), 1234-1245 (2010).
156. Li CY, Wu T, Li QN et al. [Quantitative study on the effect of osthole on proximal tibiae in ovariectomized (OVX) rats]. Yao Xue Xue Bao 31(5), 327-332 (1996). (Pubitemid 126436239)
157. Yang L, Wang NL, Cai GP. Maohuoside A promotes osteogenesis of rat mesenchymal stem cells via BMP and MAPK signaling pathways. Mol. Cell. Biochem. 358(1-2), 37-44 (2011).
158. Lee HW, Suh JH, Kim HN et al. Berberine promotes osteoblast differentiation by Runx2 activation with p38 MAPK. J. Bone Miner. Res. 23(8), 1227-1237 (2008).
159. Dai Z, Li Y, Quarles LD et al. Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine 14(12), 806-814 (2007). (Pubitemid 350017876)
160. Sakamoto S, Kojima F, Igarashi M et al. Decalpenic acid, a novel small molecule from Penicillium verruculosum CR37010, induces early osteoblastic markers in pluripotent mesenchymal cells. J. Antibiot. (Tokyo) 63(12), 703-708 (2010).
161. Uchiyama S, Yamaguchi M. Beta-cryptoxanthin stimulates cell differentiation and mineralization in osteoblastic MC3T3-E1 cells. J. Cell. Biochem. 95(6), 1224-1234 (2005). (Pubitemid 41420129)
162. Harada SI, Balena R, Rodan GA, Rodan SB. The role of prostaglandins in bone formation. Connect. Tissue Res. 31(4), 279-282 (1995).
163. Knippenberg M, Helder MN, de Blieck-Hogervorst JM, Wuisman PI, Klein-Nulend J. Prostaglandins differentially affect osteogenic differentiation of human adipose tissue-derived mesenchymal stem cells. Tissue Eng. 13(10), 2495-2503 (2007). (Pubitemid 47571708)
164. Wong RW, Rabie AB. Effect of naringin on bone cells. J. Orthop. Res. 24(11), 2045-2050 (2006). (Pubitemid 44717966)
165. Pang WY, Wang XL, Mok SK et al. Naringin improves bone properties in ovariectomized mice and exerts oestrogen-like activities in rat osteoblast-like (UMR-106) cells. Br. J. Pharmacol. 159(8), 1693-1703 (2010).
166. Kim YJ, Bae YC, Suh KT, Jung JS. Quercetin, a flavonoid, inhibits proliferation and increases osteogenic differentiation in human adipose stromal cells. Biochem. Pharmacol. 72(10), 1268-1278 (2006). (Pubitemid 44572193)
167. Wong RW, Rabie AB. Effect of quercetin on preosteoblasts and bone defects. Open Orthop. J. 2, 27-32 (2008).
168. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 105(6), 739-745 (2002). (Pubitemid 34157379)
169. Shiota M, Hikita Y, Kawamoto Y et al. Pravastatin-induced proangiogenic effects depend upon extracellular FGF-2. J. Cell. Mol. Med. doi:10.1111/j.1582- 4934.2011.01494.x (2011) (Epub ahead of print).
170. Llevadot J, Asahara T. [Effects of statins on angiogenesis and vasculogenesis]. Rev. Esp. Cardiol. 55(8), 838-844 (2002).
171. Chung BH, Kim JD, Kim CK et al. Icariin stimulates angiogenesis by activating the MEK/ERK-and PI3K/Akt/eNOS-dependent signal pathways in human endothelial cells. Biochem. Biophys. Res. Commun. 376(2), 404-408 (2008).
172. Rivron NC, Raiss CC, Liu J et al. Sonic Hedgehog-activated engineered blood vessels enhance bone tissue formation. Proc. Natl Acad. Sci. USA 109(12), 4413-4418 (2012).
173. Zhang S, Chen S, Shen Y et al. Puerarin induces angiogenesis in myocardium of rat with myocardial infarction. Biol. Pharm. Bull. 29(5), 945-950 (2006).
174. Mehrabi MR, Serbecic N, Tamaddon F et al. Clinical and experimental evidence of prostaglandin E1-induced angiogenesis in the myocardium of patients with ischemic heart disease. Cardiovasc. Res. 56(2), 214-224 (2002). (Pubitemid 35223492)
175. Pillai A, Mahadik SP. Differential effects of haloperidol and olanzapine on levels of vascular endothelial growth factor and angiogenesis in rat hippocampus. Schizophr. Res. 87(1-3), 48-59 (2006). (Pubitemid 44428128)
176. Chen KM, Ge BF, Liu XY et al. Icariin inhibits the osteoclast formation induced by RANKL and macrophage-colony stimulating factor in mouse bone marrow culture. Pharmazie 62(5), 388-391 (2007). (Pubitemid 46847945)
177. Yamagami H, Nishioka T, Ochiai E et al. Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E2. Biochem. Pharmacol. 66(5), 801-807 (2003). (Pubitemid 37011419)
178. Staal A, Frith JC, French MH et al. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J. Bone Miner. Res. 18(1), 88-96 (2003). (Pubitemid 36008343)
179. Moon HJ, Kim SE, Yun YP et al. Simvastatin inhibits osteoclast differentiation by scavenging reactive oxygen species. Exp. Mol. Med. 43(11), 605-612 (2011).
180. Igarashi K, Hirotani H, Woo JT, Stern PH. Cyclosporine A and FK506 induce osteoclast apoptosis in mouse bone marrow cell cultures. Bone 35(1), 47-56 (2004). (Pubitemid 38789147)
181. Smink JJ, Tunn P-U, Leutz A. Rapamycin inhibits osteoclast formation in giant cell tumor of bone through the C/EBP{beta}- MafB axis. J. Mol. Med. 90(1), 25-30 (2011).
182. Zhang Q, Qin L, He W et al. Coumarins from Cnidium monnieri and their antiosteoporotic activity. Planta Med. 73(1), 13-19 (2007). (Pubitemid 46909846)
183. Hu JP, Nishishita KS, Yoshida H et al. Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways. Eur. J. Pharmacol. 580(1-2), 70-79 (2008).
184. He X, Andersson G, Lindgren U, Li Y. Resveratrol prevents RANKL-induced osteoclast differentiation of murine osteoclast progenitor RAW 264.7 cells through inhibition of ROS production. Biochem. Biophys. Res. Commun. 401(3), 356-362 (2010).
185. Take I, Kobayashi Y, Yamamoto Y et al. Prostaglandin E2 strongly inhibits human osteoclast formation. Endocrinology 146(12), 5204-5214 (2005). (Pubitemid 41653034)
186. Wattel A, Kamel S, Prouillet C et al. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1. J. Cell. Biochem. 92(2), 285-295 (2004).
187. Ang ES, Yang X, Chen H, Liu Q, Zheng MH, Xu J. Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-kappaB and ERK activation. FEBS Lett. 585(17), 2755-2762 (2011).
188. Uchiyama S, Yamaguchi M. Beta-cryptoxanthin stimulates apoptotic cell death and suppresses cell function in osteoclastic cells: Change in their related gene expression. J. Cell. Biochem. 98(5), 1185-1195 (2006). (Pubitemid 44128358)